<DOC>
	<DOCNO>NCT01434095</DOCNO>
	<brief_summary>A half-dose photodynamic therapy , relative new treatment , widely perform treat central serous chorioretinopathy . The researcher aim investigate whether therapy improve patient 's visual acuity well retinal sensitivity . The researcher also investigate clinical factor , , associate result ; visual acuity retinal sensitivity treatment .</brief_summary>
	<brief_title>Microperimetric Evaluation After Half-dose Photodynamic Therapy Chronic Central Serous Chorioretinopathy</brief_title>
	<detailed_description>The best-corrected visual acuity ( BCVA ) , macular sensitivity , fixation stability evaluate baseline 1 , 3 , 6 , 12 month half-dose photodynamic therapy . The macular sensitivity fixation stability determine MP-1 microperimetry ( Nidek , Vigonza , Italy ) . The researcher analyse whether BCVA retinal sensitivity significantly improve . And yes , researcher interested period treatment significant improvement find . Also , researcher investigate improved first , BCVA retinal sensitivity .</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<criteria>presence subretinal fluid involve fovea Optical coherence tomographic ( OCT ) image serous retinal detachment least 6 month duration . evidence choroidal neovascularization ( CNV ) , polypoidal choroidal vasculopathy , maculopathy document fluorescein angiography Indocyanine green angiography</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>microperimetry</keyword>
	<keyword>fixation point</keyword>
	<keyword>retinal sensitivity</keyword>
	<keyword>photodynamic therapy</keyword>
	<keyword>chronic central serous chorioretinopathy</keyword>
</DOC>